Dergiler / Türk Patoloji Dergisi / 2017 / Cilt: 33 - Sayı: 2

TERT Expression in Pituitary Adenomas

Sayfa
103–111
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further studies, including combined methods of immunohistochemistry and molecular analyses in larger groups, may reveal applicable results for the clinical significance of TErT in pituitary adenomas.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Although pituitary adenomas have benign histomorphological features, some of them may present in an aggressive manner.
📊
Temel Bulgular & Veri:This study aims to investigate whether immunohistochemical expression of TErT differs in neoplastic and nonneoplastic pituitary tissues and aims to investigate whether TErT expression is related to clinicopathological features of pituitary adenomas.Material and Method: The study included 48 patients who had been diagnosed with pituitary adenomas and had clinical follow-ups. nonneoplastic pituitary tissues were obtained from autopsy specimens (n=20).
💡
Sonuç & Katkı:Further studies, including combined methods of immunohistochemistry and molecular analyses in larger groups, may reveal applicable results for the clinical significance of TErT in pituitary adenomas.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Although pituitary adenomas have benign histomorphological features, some of them may present in an aggressive manner. To predict the behaviour of these tumours, telomerase reverse transcriptase (TErT) activity in pituitary adenomas has been the subject of a few studies with contradictory results. This study aims to investigate whether immunohistochemical expression of TErT differs in neoplastic and nonneoplastic pituitary tissues and aims to investigate whether TErT expression is related to clinicopathological features of pituitary adenomas.Material and Method: The study included 48 patients who had been diagnosed with pituitary adenomas and had clinical follow-ups. nonneoplastic pituitary tissues were obtained from autopsy specimens (n=20). Immunohistochemistry for TErT antibody was performed. Both the nuclear and cytoplasmic expression of TErT antibody was noted, and total combined TErT staining was evaluated according to nuclear and cytoplasmic stainings. Results: TErT expression did not differ between neoplastic and nonneoplastic pituitary tissues. neither total (combined nuclear and cytoplasmic) TErT nor nuclear TErT expression revealed any statistically significant relationship with any of the clinicopathological features. Higher cytoplasmic TErT expression was observed in adenomas with recurrence than adenomas without recurrence (p=0.035).Conclusion: This study introduces the notion that immunohistochemical expression of TErT does not differ in neoplastic and nonneoplastic pituitary tissues. Pituitary adenomas with cytoplasmic immunohistochemical expression of TErT have significantly higher rates of recurrence. Further studies, including combined methods of immunohistochemistry and molecular analyses in larger groups, may reveal applicable results for the clinical significance of TErT in pituitary adenomas.

🔖

Bu Makaleye Atıf Yap

SÜT, N., ÇELİK, M., ÖZYILMAZ, F., KUTLU, A. K., YALTA, T. D., PUYAN, F. Ö., AYTÜRK, S., GÜLDİKEN, S., CAN, N., SARIKAŞ, N., BÜLBÜL, B. Y. (2022). TERT Expression in Pituitary Adenomas. Türk Patoloji Dergisi, Cilt: 33 - Sayı: 2, 103–111. https://ajindex.com/articles/640511

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol. 2012;49:R69-78
  2. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: A systematic review. Cancer. 2004;101:613-9
  3. Ortiz-Plata A, Tena Suck ML, Lopez-Gomez M, Heras A, Sanchez Garcia A. Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics. J Neurooncol. 2007;84:159-66
  4. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Baranger D, Raverot G, Belin MF, Lachuer J, Trouillas J. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer. 2007;14:887- 900
  5. DeLellis RA. Pathology and genetics of tumours of endocrine organs. Lyon:IARC Press; 2004
  6. Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol. 2012;22:443-53
  7. Gomez-Hernandez K, Ezzat S, Asa SL, Mete O. Clinical implications of accurate subtyping of pituitary adenomas: Perspectives from the treating physician. Turk Patoloji Derg. 2015;31 Suppl 1:4-17
  8. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986;65:733-44
  9. Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J. Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol. 2010;326:30-9
  10. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, Trouillas J, Lachuer J. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol. 2011;21:533-43
  11. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22:757-64
  12. Mete O, Hayhurst C, Alahmadi H, Monsalves E, Gucer H, Gentili F, Ezzat S, Asa SL, Zadeh G. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr Pathol. 2013;24:191-8
  13. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro